AC Immune (ACIU) Enterprise Value (2014 - 2025)
AC Immune (ACIU) reported Enterprise Value of -$114.3 million for Q4 2025, up 39.47% year-over-year from -$82.0 million in Q4 2024, and up 15.67% on a QoQ basis from -$135.6 million in Q3 2025.
AC Immune (ACIU) has 12 years of Enterprise Value data on file, last reported at -$114.3 million in Q4 2025.
- Quarterly Enterprise Value rose 39.47% year-over-year to -$114.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$114.3 million (up 39.47% YoY) and the FY2025 annual result came in at -$110.2 million, up 41.65% from the prior year.
- Enterprise Value rose to -$114.3 million in Q4 2025 per ACIU's latest filing, from -$135.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at $32.8 million in Q2 2021 and bottomed at -$125.9 billion in Q4 2021.
- The 5-year median for Enterprise Value is -$131.4 million (2025), against an average of -$10.0 billion.
- Peak annual rise in Enterprise Value reached 116.85% in 2021, while the deepest fall reached 50282.19% in 2021.
- Tracing ACIU's Enterprise Value over 5 years: stood at -$125.9 billion in 2021, then surged by 99.9% to -$127.2 million in 2022, then fell by 28.41% to -$163.4 million in 2023, then declined by 15.61% to -$188.9 million in 2024, then soared by 39.47% to -$114.3 million in 2025.
- Per Business Quant, the three latest ACIU Enterprise Value figures stand at -$114.3 million (Q4 2025), -$135.6 million (Q3 2025), and -$166.3 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -114.35 Mn |
| Sep 30, 2025 | -135.60 Mn |
| Jun 30, 2025 | -166.31 Mn |
| Mar 31, 2025 | -161.96 Mn |
| Dec 31, 2024 | 78.06 Mn |
| Sep 30, 2024 | 79.07 Mn |
| Jun 30, 2024 | 22.68 Mn |
| Mar 31, 2024 | -38.67 Mn |
| Dec 31, 2023 | -163.40 Mn |
| Sep 30, 2023 | -84.83 Mn |
| Jun 30, 2023 | -77.39 Mn |
| Mar 31, 2023 | -108.59 Mn |
| Dec 31, 2022 | -127.25 Mn |
| Sep 30, 2022 | -66.79 Mn |
| Jun 30, 2022 | -111.32 Mn |
| Mar 31, 2022 | -188.23 Mn |
| Dec 31, 2021 | -125.89 Bn |
| Sep 30, 2021 | 32.57 Mn |
| Jun 30, 2021 | 32.79 Mn |
| Mar 31, 2021 | -71.89 Bn |
| Dec 31, 2020 | -211.16 Mn |
| Sep 30, 2020 | -218.98 Mn |
| Jun 30, 2020 | -194.55 Mn |
| Mar 31, 2020 | -287.26 Mn |
| Dec 31, 2019 | -129.92 Mn |
| Sep 30, 2019 | -154.74 Mn |
| Jun 30, 2019 | -205.13 Bn |
| Mar 31, 2019 | -172.84 Mn |
| Dec 31, 2018 | -187.36 Mn |
| Dec 31, 2017 | -126.07 Mn |
| Sep 30, 2017 | -158.18 Mn |
| Jun 30, 2017 | -154.48 Mn |
| Mar 31, 2017 | -137.53 Mn |
| Dec 31, 2016 | -152.21 Mn |
| Sep 30, 2016 | -156.02 Mn |
| Jun 30, 2016 | -156.86 Mn |
| Dec 31, 2015 | -77.33 Mn |
| Dec 31, 2014 | -3.43 Mn |